BIOLOGICAL · Unmapped registry intervention
BPX-601
Find medicine records ·
Find other trials using this name
Clinical trial
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
NCT02744287
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Rimiducid
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedSafety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Regeneron Pharmaceuticalslead sponsor
Mapped research locations
ChicagoIllinois, United States2New YorkNew York, United States1HoustonTexas, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1AtlantaGeorgia, United States1TampaFlorida, United States1DurhamNorth Carolina, United States1DetroitMichigan, United States1OmahaNebraska, United States1BuffaloNew York, United States1HackensackNew Jersey, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02744287 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.